nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2006-10-2-18-27nefr-546Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНЕФРОПРОТЕКТИВНАЯ ТЕРАПИЯ ГИПЕРТЕНЗИВНЫХ БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК: ЕСТЬ ЛИ В НЕЙ МЕСТО ДЛЯ β-АДРЕНОБЛОКАТОРОВ ТРЕТЬЕГО ПОКОЛЕНИЯ И АГОНИСТОВ I1-ИМИДАЗОЛИНОВЫХ РЕЦЕПТОРОВ?NEPHROPROTECTIVE THERAPY OF HYPERTENSIVE PATIENTS WITH CHRONIC KIDNEY DISEASE: IS THERE A PLACE FOR THE THIRD GENERATION OF β-ADRENORECEPTOR BLOCKERS AND I1-IMIDAZOLINE RECEPTOR AGONISTS?КузьминО. Б.KuzminO. B.
кафедра фармакологии
ПугаеваМ. О.PugaevaM. O.
кафедра фармакологии
ЖежаВ. В.ZhezhaV. V.
кафедра фармакологии
Оренбургская государственная медицинская академияRussian Federation2006100220061021827Copyright © Кузьмин О.Б., Пугаева М.О., Жежа В.В., 20062006Кузьмин О.Б., Пугаева М.О., Жежа В.В.Kuzmin O.B., Pugaeva M.O., Zhezha V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/546
.
.
хроническая болезнь почексимпатическая гиперактивностьсклеротическое повреждение почкиβ-адреноблокаторыагонисты I1-имидазолиновых рецепторовchronic kidney diseasesympathetic hyperactivationrenal sclerotic damageβ-adrenoreceptor blockersagonists of I1-imidazoline receptorReferencesChobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42 (6): 1206-1252Chobanian A, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension 2003; 42 (6): 1206-1252Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-1053Guidelines Committee. 2003 European Society of hypertension / European Society of cardiology guidelines for management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-1053Комитет экспертов ВНОК. Профилактика, диагностика и лечение артериальной гипертонии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 6 [Приложение]: 3-19Комитет экспертов ВНОК. Профилактика, диагностика и лечение артериальной гипертонии. Российские рекомендации (второй пересмотр). Кардиоваскулярная терапия и профилактика 2004; 6 [Приложение]: 3-19Ruggenenti P, Perna A, Loziga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN 2): multicentre, randomized controlled trial. Lancet 2005; 365 (9463): 939-946Ruggenenti P, Perna A, Loziga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN 2): multicentre, randomized controlled trial. Lancet 2005; 365 (9463): 939-946Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 13-21Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29 (1): 13-21Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47 (11): 1936-1939.Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47 (11): 1936-1939.Eppel GA, Malpas SC, Denton KM, Evans RG. Neural control of renal medullary perfusion. Clin Exp Pharmacol Physiol 2004; 31 (5-6): 387-396Eppel GA, Malpas SC, Denton KM, Evans RG. Neural control of renal medullary perfusion. Clin Exp Pharmacol Physiol 2004; 31 (5-6): 387-396Barajas L, Powers K, Wang P. Innervation of renal cortical tubules: a quantitative study. Am J Physiol 1984; 247 (1): F30-F60Barajas L, Powers K, Wang P. Innervation of renal cortical tubules: a quantitative study. Am J Physiol 1984; 247 (1): F30-F60Cohen HT, Takemoto F, Satoh T, Katz AI. Renal adrenergic receptors: localization of 125 Iprasosin binding sites along the microdissected rat nephron. Can J Physiol Pharmacol 1992; 70 (7): 1016-1020Cohen HT, Takemoto F, Satoh T, Katz AI. Renal adrenergic receptors: localization of 125 Iprasosin binding sites along the microdissected rat nephron. Can J Physiol Pharmacol 1992; 70 (7): 1016-1020Struyker-Boudier HA, Janssen BJ, Smiths JF. Adrenoreceptors in the kidney: localization and pharmacology. Clin Exp Hypertens 1987; A9, [Suppl 1]: 135-150Struyker-Boudier HA, Janssen BJ, Smiths JF. Adrenoreceptors in the kidney: localization and pharmacology. Clin Exp Hypertens 1987; A9, [Suppl 1]: 135-150Wang TT, Chen X, Wu XH et al. Molecular mechanism of action of isoprotorenol on the expression of angiotensinogen gene in opossum kidney proximal tubular cells. Kidney Int 1999; 55 (5): 1713-1723Wang TT, Chen X, Wu XH et al. Molecular mechanism of action of isoprotorenol on the expression of angiotensinogen gene in opossum kidney proximal tubular cells. Kidney Int 1999; 55 (5): 1713-1723Wolf G, Helmchen U, Stahl RA. Isoprotorenol stimulates tubular DNA replication in mice. Nephrol Dial Transplant 1996; 11 (11): 2288-2292Wolf G, Helmchen U, Stahl RA. Isoprotorenol stimulates tubular DNA replication in mice. Nephrol Dial Transplant 1996; 11 (11): 2288-2292Nakamura A, Imaizumi A, Yanagawa Y et al. Suppression of tumor necrosis factor-alpha by І 2-adrenoceptor activation: role of mitogen-activated protein kinases in renal mesangial cells. Inflam Res2003; 52 (1): 26-31Nakamura A, Imaizumi A, Yanagawa Y et al. Suppression of tumor necrosis factor-alpha by І 2-adrenoceptor activation: role of mitogen-activated protein kinases in renal mesangial cells. Inflam Res2003; 52 (1): 26-31Nakamura A, Imaizumi A, Yanagawa Y. Beta 2-adrenoceptor function in the kidney. Nippon Yakurigaki zasshi 2004; 124 (6): 427-434Nakamura A, Imaizumi A, Yanagawa Y. Beta 2-adrenoceptor function in the kidney. Nippon Yakurigaki zasshi 2004; 124 (6): 427-434Tinucci T, Abrahao SB, Santello JL, Mion D. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15 (6): 401-406Tinucci T, Abrahao SB, Santello JL, Mion D. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15 (6): 401-406Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity inappropriately increased in chronic renal disease. J Am Soc Nephrol2003; 14 (12): 3239-3244Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity inappropriately increased in chronic renal disease. J Am Soc Nephrol2003; 14 (12): 3239-3244Zoccali C, Mallamaci F, Parlengo S et al. Plasma norepinephrine predict survival and incident cardiovascular events in patients with end stage renal disease. Circulation 2002; 105 (11): 1354-1359Zoccali C, Mallamaci F, Parlengo S et al. Plasma norepinephrine predict survival and incident cardiovascular events in patients with end stage renal disease. Circulation 2002; 105 (11): 1354-1359Hansberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end stage renal disease. Circulation 2002; 106 (15): 1974-1979Hansberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end stage renal disease. Circulation 2002; 106 (15): 1974-1979Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25 (4): 878-882Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25 (4): 878-882Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997; 99 (3): 540-548Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J Clin Invest 1997; 99 (3): 540-548Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 2002; 4 (3): 256-260Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 2002; 4 (3): 256-260Miyajima E, Yamada Y, Yoshida Y et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17 (6): 1057-1062Miyajima E, Yamada Y, Yoshida Y et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17 (6): 1057-1062Modlinger PC, Wilcox CS, Aslam S. Nitric oxide, oxidative stress and progressive of chronic renal failure. Semin Nephrol 2004; 24 (4): 354-365Modlinger PC, Wilcox CS, Aslam S. Nitric oxide, oxidative stress and progressive of chronic renal failure. Semin Nephrol 2004; 24 (4): 354-365Campese VM, Shaohua Ye, Huinqin Zhong et al. Reactive oxygen species stimulate central and peripheral sympathetic nervous system. Am J Physiol 2004; 287 (2): H795-H703Campese VM, Shaohua Ye, Huinqin Zhong et al. Reactive oxygen species stimulate central and peripheral sympathetic nervous system. Am J Physiol 2004; 287 (2): H795-H703Stegbauer J, Vonend O, Obehauser V et al. Angiotensin II receptor modulation of renal vascular resis itance and neurotransmission in young and adult spontaneously hypertensive rats. Kidney Blood Press Res 2005; 28 (1): 20-26Stegbauer J, Vonend O, Obehauser V et al. Angiotensin II receptor modulation of renal vascular resis itance and neurotransmission in young and adult spontaneously hypertensive rats. Kidney Blood Press Res 2005; 28 (1): 20-26Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14 (2): 425-430Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14 (2): 425-430Eikelis N, Schlaich M, Aggarwal A et al. Interaction between leptin and human sympathetic nervous system. Hypertension 2003; 41 (5): 1072-1079Eikelis N, Schlaich M, Aggarwal A et al. Interaction between leptin and human sympathetic nervous system. Hypertension 2003; 41 (5): 1072-1079Montanaro MS, Allen AM, Oldfield BJ. Structural and functional evidence supporting a role for leptin in central neural pathways influencing blood pressure in rats. Exp Physio l2005; 90 (5): 689-696Montanaro MS, Allen AM, Oldfield BJ. Structural and functional evidence supporting a role for leptin in central neural pathways influencing blood pressure in rats. Exp Physio l2005; 90 (5): 689-696Scharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51 (6): 1980-1985Scharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51 (6): 1980-1985Merabet E, Dagogo-Jack S, Coyne DW et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1999; 82 (3): 847-850Merabet E, Dagogo-Jack S, Coyne DW et al. Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 1999; 82 (3): 847-850Кузьмин ОБ, Пугаева МО, Чуб СВ, Ландарь ЛН. Почечные механизмы эссенциальной гипертонии. Нефрология 2005; 9 (2): 23-29Кузьмин ОБ, Пугаева МО, Чуб СВ, Ландарь ЛН. Почечные механизмы эссенциальной гипертонии. Нефрология 2005; 9 (2): 23-29Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7-15Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9 (3): 7-15Ермаков ЮА, Вишняков НИ, Ковальский ГБ. Хроническая почечная недостаточность у нефрологических больных в Санкт-Петербурге по данным патологоанатомических исследований за 1993–2003 годы. Нефрология 2005; 9 (2): 78-82Ермаков ЮА, Вишняков НИ, Ковальский ГБ. Хроническая почечная недостаточность у нефрологических больных в Санкт-Петербурге по данным патологоанатомических исследований за 1993–2003 годы. Нефрология 2005; 9 (2): 78-82Denton KM, Shweta A, Flower RL, Anderson WP. Predominant postglomerular vascular resistance response to reflex renal nerve stimulation during Ang II clamp in rabbits. Am J Physio l2004; 287 (4): R780-R786Denton KM, Shweta A, Flower RL, Anderson WP. Predominant postglomerular vascular resistance response to reflex renal nerve stimulation during Ang II clamp in rabbits. Am J Physio l2004; 287 (4): R780-R786Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 19 (2): 342-347Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant 2004; 19 (2): 342-347Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventicia is augmented by injury and mediated by different α1-adrenoceptor subtypes. Circulat Res 2001; 89 (9): 815-822Zhang H, Faber JE. Trophic effect of norepinephrine on arterial intima-media and adventicia is augmented by injury and mediated by different α1-adrenoceptor subtypes. Circulat Res 2001; 89 (9): 815-822Erami C, Zhang H, Tanoue A et al. Adrenergic catecholamine trophic activity contributes to flow-mediated arterial remodeling. Am J Physio l2005; 289 (2): H744-H753Erami C, Zhang H, Tanoue A et al. Adrenergic catecholamine trophic activity contributes to flow-mediated arterial remodeling. Am J Physio l2005; 289 (2): H744-H753Johnston RJ, Gordon KL, Suga S et al. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 1999; 34 (1): 151-159Johnston RJ, Gordon KL, Suga S et al. Renal injury and salt-sensitive hypertension after exposure to catecholamines. Hypertension 1999; 34 (1): 151-159Nakamura A, Imaizumi A, Yanagawa Y et al. β2-Adrenoceptor activation attenuates endotoxin-induced acute renal failure. J Am Soc Nephrol 2004; 15 (2): 316-325Nakamura A, Imaizumi A, Yanagawa Y et al. β2-Adrenoceptor activation attenuates endotoxin-induced acute renal failure. J Am Soc Nephrol 2004; 15 (2): 316-325Bohlen L, de Courten M, Weidmann P. Comparative study of the effects of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7 (9, Pt2): 84S-92SBohlen L, de Courten M, Weidmann P. Comparative study of the effects of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7 (9, Pt2): 84S-92SGansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963-1974Gansevoort RT, Sluiter WJ, Hemmelder MH et al. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 1995; 10 (11): 1963-1974Kalinowski L, Dobrucki LW, Szczeppanska-Konkel M et al. Third-generation beta-blockers stimulate nitric oxide release from epithelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107 (21): 2747-2752Kalinowski L, Dobrucki LW, Szczeppanska-Konkel M et al. Third-generation beta-blockers stimulate nitric oxide release from epithelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107 (21): 2747-2752Wong VY, Laping NJ, Nelson AH et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Brit J Pharmacol 2001; 134 (5): 977-984Wong VY, Laping NJ, Nelson AH et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Brit J Pharmacol 2001; 134 (5): 977-984Van den Branden C, Gabriels M, Vamecq J et al. Carvedilol protects against glomerulosclerosis in the rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs carvedilol and propranolol. Nephron 1997; 77 (3): 319-324Van den Branden C, Gabriels M, Vamecq J et al. Carvedilol protects against glomerulosclerosis in the rat remnant kidney without general changes in antioxidant enzyme status. A comparative study of two beta-blocking drugs carvedilol and propranolol. Nephron 1997; 77 (3): 319-324Rodriques-Peres JC, Losada A, Anabitarte A et al. Effects of novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablation rats. J Pharmacol Exp Ther 1997; 283 (1): 336-344Rodriques-Peres JC, Losada A, Anabitarte A et al. Effects of novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablation rats. J Pharmacol Exp Ther 1997; 283 (1): 336-344Tomita K, Marumo F. Effect of long-term carvedolol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992; 19 [Suppl 1]: S97-S101Tomita K, Marumo F. Effect of long-term carvedolol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992; 19 [Suppl 1]: S97-S101Zitta S, Stoschitzky K, Zweiker R et al. Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension. Nephrol Dial Transplant 2000; 15 (8): 1162-1169Zitta S, Stoschitzky K, Zweiker R et al. Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension. Nephrol Dial Transplant 2000; 15 (8): 1162-1169Marchi F, Ciriello G. Efficacy of carvedolol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12 (4): 212-221Marchi F, Ciriello G. Efficacy of carvedolol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12 (4): 212-221Fassbinder W, Quarter O, Waltz A. Treatment with carvedolol is associated with a significant reduction in microalbuminuria: a multicentre randomized study. Int J Clin Pract 1999; 53 (7): 515-522Fassbinder W, Quarter O, Waltz A. Treatment with carvedolol is associated with a significant reduction in microalbuminuria: a multicentre randomized study. Int J Clin Pract 1999; 53 (7): 515-522Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46 (6): 1309-1315Bakris GL, Fonseca V, Katholi RE et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46 (6): 1309-1315Kramer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedolol in patients with chronic renal failure. Eur J Pharmacol 1992; 43 (1): 85-88Kramer BK, Ress KM, Erley CM, Risler T. Pharmacokinetic and blood pressure effects of carvedolol in patients with chronic renal failure. Eur J Pharmacol 1992; 43 (1): 85-88Janssen BJA, Lukoshkova EV, Head GA. Sympathetic modulation of renal blood flow by rilmenidine and captopril: central vs. peripheral effects. Am J Physiol 2002; 282 (1): F113-F123Janssen BJA, Lukoshkova EV, Head GA. Sympathetic modulation of renal blood flow by rilmenidine and captopril: central vs. peripheral effects. Am J Physiol 2002; 282 (1): F113-F123Smyth DD, Pirnat D, Forzley B, Penner SB. Apparent absence of direct renal effects of imidazoline receptor agonist. Ann NY Acad Sci 2003; 1009 (1): 288-295Smyth DD, Pirnat D, Forzley B, Penner SB. Apparent absence of direct renal effects of imidazoline receptor agonist. Ann NY Acad Sci 2003; 1009 (1): 288-295Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats.J Am Soc Nephrol 2000; 11(8): 1469-1478Amann K, Rump LC, Simonaviciene A et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats.J Am Soc Nephrol 2000; 11(8): 1469-1478Vonend O, Apel T, Amann K et al. Modulation of gene expression by moxonidine in rat with chronic renal failure. Nephrol Dial Transplant 2004; 19 (9): 2217-2222Vonend O, Apel T, Amann K et al. Modulation of gene expression by moxonidine in rat with chronic renal failure. Nephrol Dial Transplant 2004; 19 (9): 2217-2222Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996; 11 (6): 1003-1011Amann K, Nichols C, Tornig J et al. Effect of ramipril, nifedipine and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996; 11 (6): 1003-1011Krespi PJ, Makris TK, Hatzizasharias AN et al. Moxonidine effects on microalbuminuria, thrombomodulin and plasminogen activator-I levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463-467Krespi PJ, Makris TK, Hatzizasharias AN et al. Moxonidine effects on microalbuminuria, thrombomodulin and plasminogen activator-I levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12 (5): 463-467Демидова ТЮ, Аметов АС, Смагина ЛВ, Виноградова МВ. Органопротективные свойства агониста имидазолиновых рецепторов моксонидина (физиотенза) у больных артериальной гипертонией и сахарным диабетом 2-го типа. Клин фармакол и тер 2004; 13 (5): 21-25Демидова ТЮ, Аметов АС, Смагина ЛВ, Виноградова МВ. Органопротективные свойства агониста имидазолиновых рецепторов моксонидина (физиотенза) у больных артериальной гипертонией и сахарным диабетом 2-го типа. Клин фармакол и тер 2004; 13 (5): 21-25Трусов ВВ, Аксенов КВ. Влияние агониста имидазолиновых рецепторов моксонидина на состояние микроциркуляции и функцию почек у больных артериальной гипертонией с сахарным диабетом 2-го типа. Кардиология 2003; 43 (9): 44-48Трусов ВВ, Аксенов КВ. Влияние агониста имидазолиновых рецепторов моксонидина на состояние микроциркуляции и функцию почек у больных артериальной гипертонией с сахарным диабетом 2-го типа. Кардиология 2003; 43 (9): 44-48Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type 2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000; 7 (1): 57-61Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type 2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000; 7 (1): 57-61Kirch W, Hutt HJ, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15 (4): 245-253Kirch W, Hutt HJ, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet 1988; 15 (4): 245-253Singlas E, Ehrhardt JD, Zech P et al. Pharmacokinetics of rilmenidine. Am J Cardiol 1988: 61 (7): 54D-59DSinglas E, Ehrhardt JD, Zech P et al. Pharmacokinetics of rilmenidine. Am J Cardiol 1988: 61 (7): 54D-59D
The authors declare that there are no conflicts of interest present.